spacer
home > ict > autumn 2009 > different countries, different approaches
PUBLICATIONS
International Clinical Trials

Different Countries, Different Approaches

 

Since the establishment of ICH-GCP, the globalisation of clinical trials has proven to be an irreversible trend. Pharmaceutical and biotechnology companies (mainly through CROs) are increasingly testing their candidate drugs in Latin America, eastern Europe and in the Asia-Pacific region. Each of these regions is composed of many different countries, each with their own clinical research regulations.

From an operational standpoint, it is not very difficult to reconcile the differences of clinical practices around the globe, although there are particularities. The operational implementation of a clinical protocol is basically the same from one place to another, and it is possible to conduct a global multi-centric study while maintaining the quality of the generated data.

From a legal standpoint, this same globalisation scenario can be slightly different. Legal systems may have a number of similarities, but unlike the ethical and operational aspects, legal differences are harder to standardise and globalise.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Vitor Harada is a Clinical Development professional with 11 years of experience. He graduated in Pharmacy and Biochemistry from the University of São Paulo (USP) and has a MBA from the Fundação Getulio Vargas (FGV). Vitor is currently a Director of Clinical Operations at ICON and responsible for the company’s office in Brazil. He is also President of ABRACRO (Brazilian Association of CROs) and one of the Professors/Coordinators of the Clinical Research Postgraduation Course of the Santa Casa de São Paulo Medical School. In the past, Vitor has worked for AstraZeneca (where he was the local Head of the Clinical Department), Pharmacia and Bristol-Myers Squibb.
spacer
Vitor Harada
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical Pharmacy Veteran Joins Clinical Trial Patient Solutions Team at Myonex

Myonex is proud to announce Todd Luckritz has joined Myonex as Associate Director of Clinical Trial Patient Solutions.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement